XML 25 R11.htm IDEA: XBRL DOCUMENT v3.24.1
Accounts Receivable
 12 Months Ended
Dec. 31, 2023
Credit Loss [Abstract]  
Accounts Receivable

NOTE 5—Accounts Receivable

 

The following table presents the components of the Company’s receivables:

   2023   2022 
   December 31, 
   2023   2022 
Trade receivables  $25,576   $22,546 
Allowance for credit losses   (272)   (113)
Accounts receivable, net   25,304    22,433 
Non-trade receivables   961    2,269 
Total accounts receivable  $26,265   $24,702 

 

As of January 1, 2022, accounts receivable, net, was $10,803 and non-trade receivables was $2,255.

 

The Company has non-trade receivables from manufacturing vendors resulting from the sale of components to the vendors who manufacture and assemble final products for the Company.

 

During 2023, the Company implemented ASC 326 and accrued an allowance for credit losses. The Company determined the probability of default for each pool of receivables with similar risk characteristics. The probability of loss was applied to the value of the receivables and an allowance for potential credit losses was recorded with the offset to credit loss expense.

 

The following table displays the roll forward of the allowance for credit losses on the Company’s trade receivables during the year ended December 31, 2023:

 

Beginning Balance, January 1, 2023  $113 
Provision for credit losses   159 
Ending Balance, December 31, 2023  $272 

 

Trade receivables from the customer that purchases tablets from the Company accounts for 69% and 84%, respectively, of accounts receivable, net, at December 31, 2023 and 2022. One additional customer accounted for 15% of accounts receivable, net, at December 31, 2023. In October 2023, the Company stopped sales of the tablets to this customer as the product reached the end of its life cycle. The tablet customer had a receivable due to the Company of $17,443 at December 31, 2023. In February 2024, an agreement was executed that transferred $11,308 of the receivables to the manufacturer of the tablets in exchange for relieving the Company of a $11,308 accounts payable liability. See Note 15.